Package Leaflet: Information for the User
Aricept Flas 10 mg Oral Disintegrating Tablets
Donepezil Hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Aricept Flas belongs to a group of medicines called acetylcholinesterase inhibitors. Donepezil hydrochloride increases the levels in the brain of a substance related to memory (acetylcholine) by reducing the speed of breakdown of this substance.
It is used for the treatment of symptoms of mild to moderately severe Alzheimer's disease. The symptoms include increased memory loss, confusion, and changes in behavior.
Do not take Aricept Flas:
Warnings and precautions
Consult your doctor before starting to take Aricept Flas if you have or have had:
You should avoid taking Aricept Flas with other acetylcholinesterase inhibitors and other agonists or antagonists of the cholinergic system.
Using Aricept Flas with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines, and especially if you are taking any of the following medicines:
In case of surgical intervention with general anesthesia, you should inform your doctor that you are taking Aricept Flas, as this may affect the amount of anesthetic needed.
Aricept Flas can be used in patients with mild to moderate kidney or liver disease. Inform your doctor before starting treatment if you have kidney or liver problems. Patients with severe liver disease should not take Aricept Flas.
Taking Aricept Flas with food, drinks, and alcohol
Place the tablet on the tongue and let it dissolve. Swallow with or without water.
Aricept Flas should not be taken with alcohol, as alcohol may alter the effect of this medicine.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You should not take Aricept Flas if you are breastfeeding.
Driving and using machines
Your illness may affect your ability to drive or use machines, and you should not carry out these activities unless your doctor tells you it is safe to do so. Aricept Flas may cause fatigue, dizziness, somnolence, and muscle cramps, mainly at the start of treatment or when increasing the dose. If you experience these effects, do not drive or use machines.
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
Aricept Flas is administered orally. The tablet should be placed on the tongue and allowed to dissolve before swallowing with or without water.
Treatment with Aricept Flas starts with a 5 mg tablet, taken once daily, at night, immediately before bedtime. After one month of treatment, your doctor may instruct you to increase the dose to 10 mg, once daily, at night. The maximum recommended dose is 10 mg per day.
If you have abnormal dreams, nightmares, or difficulty sleeping (see section 4), your doctor may recommend that you take Aricept Flas in the morning.
If you have mild or moderate liver or kidney impairment, you can take Aricept Flas. Inform your doctor before starting treatment if you have liver or kidney problems. Patients with severe liver impairment should not take Aricept Flas.
Use in children
Aricept Flas is not recommended for use in children.
If you take more Aricept Flas than you should
If you have taken more Aricept Flas than you should, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medicine and the amount used.
Symptoms of overdose may include nausea, vomiting, drooling, sweating, decreased heart rate, low blood pressure, breathing problems, loss of consciousness, and seizures.
If you forget to take Aricept Flas
Do not take a double dose to make up for forgotten doses.
If you stop taking Aricept Flas
Do not stop taking Aricept Flas unless your doctor tells you to. If you stop taking Aricept Flas, the benefits of treatment will gradually disappear.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Aricept Flas can cause side effects, although not everybody gets them.
The following side effects have been reported by people taking Aricept.
Contact your doctor if you have any of these side effects during treatment with Aricept.
Serious side effects:
You should inform your doctor immediately if you notice any of the following serious side effects, as you may need urgent medical treatment.
The estimated frequency of occurrence of side effects is as follows:
Very common: may affect more than 1 in 10 people
Common: may affect between 1 and 10 in 100 people
Uncommon: may affect between 1 and 10 in 1,000 people
Rare: may affect between 1 and 10 in 10,000 people
Frequency not known (cannot be estimated from the available data)
Reporting of side effects
If you experience any of these side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly to the Spanish Medicines Agency's website: www.notificaRAM.es.
Keep this medicine out of the sight and reach of children.
This medicine does not require any special storage conditions.
Do not use Aricept Flas after the expiry date stated on the carton. The expiry date is the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Aricept Flas 10 mg Oral Disintegrating Tablets
Appearance of the product and pack contents
Aricept Flas 10 mg Oral Disintegrating Tablets are available in a pack size with a unit dose blister formed by PVC/PVdC/PE/PVdC/PVC with an aluminum foil on the back, containing 28 tablets.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
Manufacturer:
Fareva Amboise
Zone Industrielle
29 route des Industries
37530 Pocé-sur-Cisse
France
or
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
You can obtain further information on this medicine by contacting the local representative of the marketing authorization holder:
Eisai Farmacéutica, S.A.
Parque Empresarial Cristalia.
Calle Via de los Poblados 3, Edf. 7/8
4th floor
28033 Madrid
Phone: + (34) 91 455 94 55
Date of last revision of this leaflet: December 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/